Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/25207
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorRojas Camargo, John Jairo-
dc.contributor.authorAristizábal, Julián-
dc.contributor.authorSánchez, Joan-
dc.date.accessioned2022-01-08T16:28:25Z-
dc.date.available2022-01-08T16:28:25Z-
dc.date.issued2013-
dc.identifier.urihttp://hdl.handle.net/10495/25207-
dc.description.abstractABSTRACT: Verapamil hydrochloride is a drug used to treat arrhythmias. In this study, a D-optimal mixture design with 16 runs was used to select the best combination of three polymers into a matrix that rendered an 8 h in vitro release profile of verapamil. hydrochloride (HCl) which fulfill a once-a-day modified release in compliance with the United States Pharmacopeia (USP) specifications. The Korsmeyer-Peppas model was used to fit the dissolution data since it presented the best fitting characteristics. A cubic model predicted the best formulation of verapamil.HCl containing carnauba wax, hydroxypropyl methyl cellulose and Avicel_PH101 at the 40, 20 and 40% levels, respectively. Validation runs confirmed the accuracy of the cubic models which include these three components.spa
dc.format.extent7spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherAcademic Journalsspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleAssessment of a modified release verapamil.HCl matrix compacts : Effect of formulation composition on the in-vitro release kineticspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupDiseño y Formulación de Medicamentos Cosméticos y Afinesspa
dc.identifier.doi10.5897/AJPP2013.3466-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1996-0816-
oaire.citationtitleAfrican Journal of Pharmacy and Pharmacologyspa
oaire.citationstartpage793spa
oaire.citationendpage800spa
oaire.citationvolume7spa
oaire.citationissue15spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
dc.publisher.placeLagos, Nigeriaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsVerapamilo-
dc.subject.decsVerapamil-
dc.subject.decsDinámicas no Lineales-
dc.subject.decsNonlinear Dynamics-
dc.subject.lembDiseño experimental-
dc.subject.lembExperimental design-
dc.subject.proposalControlled-release preparationsspa
dc.description.researchgroupidCOL0003623spa
dc.relation.ispartofjournalabbrevAfr. J. Pharm. Pharmacol.spa
Aparece en las colecciones: Artículos de Revista en Farmacéutica y Alimentarias

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
RojasJohn_2013_AssessmentModifiedVerapamil.pdfArtículo de investigación521.62 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons